mTOR inhibitors in cancer therapy

被引：259
作者：
Zaytseva, Yekaterina Y. [1 ]
Valentino, Joseph D. [1 ,2 ]
Gulhati, Pat [3 ]
Evers, B. Mark [1 ,2 ]
机构：
[1] Univ Kentucky, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA
[2] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA
[3] Univ Texas Med Branch, MD PhD Program, Galveston, TX USA
来源：
CANCER LETTERS | 2012年 / 319卷 / 01期
关键词：
mTOR; Cancer; Cancer therapy; Drug resistance; DUAL PI3K/MTOR INHIBITOR; MAMMALIAN TARGET; CELL MOTILITY; COMPLEX; GROWTH; ACTIVATION; PROLIFERATION; PATHWAY; PHOSPHORYLATION; RICTOR;
D O I：
10.1016/j.canlet.2012.01.005
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The mammalian target of rapamycin (mTOR) plays a key role in regulation of cellular metabolism, growth, and proliferation. The frequent hyperactivation of mTOR signaling makes it an attractive target for therapeutic intervention and has driven the development of a number of mTOR inhibitors. Encouraging data from preclinical studies have resulted in initiation of multiple clinical trials. Furthermore, combinational strategies are being studied in an effort to overcome resistance and enhance efficacy. Although additional studies are required to determine their specific role in the clinical setting, mTOR inhibitors remain a promising therapeutic option for the treatment of cancer. (c) 2012 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码：1 / 7
页数：7
相关论文
共 61 条
  • [1] Abraham R.T., 2009, SEMIN ONCOL, V36, P3, DOI 10.1053/j.seminoncol.2009.10.011
  • [2] Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
    Alvarado, Yesid
    Mita, Monica M.
    Vemulapalli, Sushma
    Mahalingam, Devalingam
    Mita, Alain C.
    [J]. TARGETED ONCOLOGY, 2011, 6 (02) : 69 - 94
  • [3] Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors
    Capdevila, Jaume
    Salazar, Ramon
    Halperin, Irene
    Abad, Albert
    Yao, James C.
    [J]. CANCER AND METASTASIS REVIEWS, 2011, 30 (01) : 27 - 34
  • [4] Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/JCI34739, 10.1172/jCI34739]
  • [5] Targeting the mTOR signaling network in cancer
    Chiang, Gary G.
    Abraham, Robert T.
    [J]. TRENDS IN MOLECULAR MEDICINE, 2007, 13 (10) : 433 - 442
  • [6] Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation
    Choo, Andrew Y.
    Yoon, Sang-Oh
    Kim, Sang Gyun
    Roux, Philippe P.
    Blenis, John
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (45) : 17414 - 17419
  • [7] Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake
    Edinger, AL
    Thompson, CB
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2002, 13 (07) : 2276 - 2288
  • [8] mTOR and cancer: many loops in one pathway
    Efeyan, Alejo
    Sabatini, David M.
    [J]. CURRENT OPINION IN CELL BIOLOGY, 2010, 22 (02) : 169 - 176
  • [9] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    Engelman, Jeffrey A.
    Chen, Liang
    Tan, Xiaohong
    Crosby, Katherine
    Guimaraes, Alexander R.
    Upadhyay, Rabi
    Maira, Michel
    McNamara, Kate
    Perera, Samanthi A.
    Song, Youngchul
    Chirieac, Lucian R.
    Kaur, Ramneet
    Lightbown, Angela
    Simendinger, Jessica
    Li, Timothy
    Padera, Robert F.
    Garcia-Echeverria, Carlos
    Weissleder, Ralph
    Mahmood, Umar
    Cantley, Lewis C.
    Wong, Kwok-Kin
    [J]. NATURE MEDICINE, 2008, 14 (12) : 1351 - 1356
  • [10] Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
    Foster, Kathryn G.
    Fingar, Diane C.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (19) : 14071 - 14077
1234567